Show simple item record

dc.contributor.authorColdiron, ME
dc.contributor.authorVon Seidlein, L
dc.contributor.authorGrais, RF
dc.date.accessioned2017-12-20T23:49:41Z
dc.date.available2017-12-20T23:49:41Z
dc.date.issued2017-11-28
dc.date.submitted2017-12-15
dc.identifier.citationSeasonal Malaria Chemoprevention: successes and missed opportunities. 2017, 16 (1):481 Malar. J.en
dc.identifier.issn1475-2875
dc.identifier.pmid29183327
dc.identifier.doi10.1186/s12936-017-2132-1
dc.identifier.urihttp://hdl.handle.net/10144/619048
dc.description.abstractSeasonal malaria chemoprevention (SMC) was recommended in 2012 for young children in the Sahel during the peak malaria transmission season. Children are given a single dose of sulfadoxine/pyrimethamine combined with a 3-day course of amodiaquine, once a month for up to 4 months. Roll-out and scale-up of SMC has been impressive, with 12 million children receiving the intervention in 2016. There is evidence of its overall benefit in routine implementation settings, and a meta-analysis of clinical trial data showed a 75% decrease in clinical malaria compared to placebo. SMC is not free of shortcomings. Its target zone includes many hard-to-reach areas, both because of poor infrastructure and because of political instability. Treatment adherence to a 3-day course of preventive treatment has not been fully documented, and could prove challenging. As SMC is scaled up, integration into a broader, community-based paradigm which includes other preventive and curative activities may prove beneficial, both for health systems and for recipients.
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsPublished by BioMed Central, [url]http://www.malariajournal.com/[/url] Archived on this site by Open Access permissionen
dc.titleSeasonal Malaria Chemoprevention: successes and missed opportunitiesen
dc.identifier.journalMalaria Journalen
refterms.dateFOA2019-03-04T13:40:02Z
html.description.abstractSeasonal malaria chemoprevention (SMC) was recommended in 2012 for young children in the Sahel during the peak malaria transmission season. Children are given a single dose of sulfadoxine/pyrimethamine combined with a 3-day course of amodiaquine, once a month for up to 4 months. Roll-out and scale-up of SMC has been impressive, with 12 million children receiving the intervention in 2016. There is evidence of its overall benefit in routine implementation settings, and a meta-analysis of clinical trial data showed a 75% decrease in clinical malaria compared to placebo. SMC is not free of shortcomings. Its target zone includes many hard-to-reach areas, both because of poor infrastructure and because of political instability. Treatment adherence to a 3-day course of preventive treatment has not been fully documented, and could prove challenging. As SMC is scaled up, integration into a broader, community-based paradigm which includes other preventive and curative activities may prove beneficial, both for health systems and for recipients.


Files in this item

Thumbnail
Name:
2017 Coldiron ME - Seasonal ...
Size:
847.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record